Clonality was assessed in the context of immune-related adverse events (irAEs) after anti-CTLA-4 treatment of prostate cancer patients, showing that the expansion more than 55 CD8+ T-cell clones in the peripheral blood preceded the development of severe irAEs (140). The gene discussed is CTLA4; the disease is prostate carcinoma.